783P Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- (1L) or second-line (2L) PD-1 and PD-L1 inhibitors in the United States (US).

Authors :: Boyd, M.
Annavarapu, S.
Doshi, G.K.
Imai, K.
Sbar, E.I.
Godwin, J.L.
Li, H.
Sonpavde, G.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS599-S599. 1p.
Publication Year :: 2020

Subjects :: *TREATMENT effectiveness
*TRANSITIONAL cell carcinoma
*PROGRAMMED cell death 1 receptors
*PROGRAMMED death-ligand 1
*METASTASIS

Full Text Access

Tools